Skip to main content
Menu
US

NeoLSD MSMS kit

The NeoLSD™ MSMS Kit is intended for the quantitative measurement of the activity of the enzymes acid-β-glucocerebrosidase (ABG), acid-sphingomyelinase (ASM), acid α glucosidase (GAA), β galactocerebrosidase (GALC), α-galactosidase A (GLA) and α-L-iduronidase (IDUA) in dried blood spots (DBS) from newborn babies.

Products may not be licensed in accordance with their laws in all countries, such as Canada. Please check with your local representative for availability.

Feature Specification
Application Newborn Screening

The NeoLSD™ MSMS Kit is intended for the quantitative measurement of the activity of the enzymes acid-β-glucocerebrosidase (ABG), acid-sphingomyelinase (ASM), acid α glucosidase (GAA), β galactocerebrosidase (GALC), α-galactosidase A (GLA) and α-L-iduronidase (IDUA) in dried blood spots (DBS) from newborn babies.

Products may not be licensed in accordance with their laws in all countries, such as Canada. Please check with your local representative for availability.

Product Variant
Unit Size: 1 kit
Part #:
3093-001U
Request More Information

Overview

The first commercial IVD kit for newborn screening of Pompe, MPS-I, Fabry, Gaucher, Niemann-Pick A/B and Krabbe disorders from a single DBS sample.

Due to advancements in treatments of lysosomal storage disorders and the subsequently increasing demand for newborn screening of these disorders, we are proud to release the NeoLSD MSMS Kit, the first commercial mass spectrometry based IVD kit for newborn screening of up to six lysosomal storage disorders from a single blood spot punch. The analysis of the enzymatic activity is intended as an aid in screening newborns for the following lysosomal storage disorders respectively; Gaucher Disease, Niemann-Pick A/B Disease, Pompe Disease, Krabbe Disease, Fabry Disease, and MPS I Disease.

The NeoLSD MSMS kit enables running up to 500 tests per instrument per day and easily switching between NeoBase™ 2 and NeoLSD™ kits on a single MSMS instrument. In addition, the NeoLSD kit provides you a wide analytical range, leading to potentially lower false positive rates, less costs associated with repeat enzyme activity tests and molecular testing.

The Benefits of the assay are as below:

  • Screen for up to six LSDs from a single DBS punch and single incubation thereby saving time, human resources and consumables
  • Provides wide dynamic range enabling better separation of affected and non-affected individuals
  • High sample volume per day to meet the rising demand of newborn screening

The kit includes all necessary for effective LSD newborn screen. It comes equipped with 3 packages.

Specifications

Application
Newborn Screening
Brand
NeoLSD™ MSMS Kit
Detection Modality
Mass Spectrometry (MSMS)
Disorders
Fabry
Gaucher
Krabbe
MPS-I
Niemann-Pick A/B
Pompe
Instrument Compatibility
QSight
Sample Type
Dried blood spots
Technology
Mass Spectrometry
Unit Size
1 kit

Image gallery

Resources

Are you looking for resources, click on the resource type to explore further.

Scroll Icon